Full Year 2023 Investor Presentation
77
Investor presentation
Full year 2023
Novo NordiskⓇ
Semaglutide 2.4 mg demonstrated superior improvement on the
primary endpoint of KCCQ-CSS vs placebo in the STEP HFPEF trial
Superior improvement in KCCQ-CSS score in patients treated with semaglutide 2.4 mg
Mean baseline KCCQ-CSS score: 56.7
20
20
•
16.6
Primary endpoints:
Key highlights
KCCQ-CSS estimated treatment difference between
semaglutide 2.4 mg and placebo of 7.8
Change in KCCQ-CSS (score)
15
10
5
20
36
Time since randomisation (weeks)
8.7
52
52*
Semaglutide 2.4mg Placebo
1 Spertus JA, et al. JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390.
KCCQ in perspective
Clinicians' assessments of clinical change¹:
•
.
•
Small: +5 points
Moderate-to-large: +10 points
Large-to-very large: +20 points
Patients' self-classifications of improvements¹:
Minimal clinically important difference for
'little improvement': 4.5 points
Note: Data shown is the treatment policy estimand. *Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation
KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical summary scoreView entire presentation